Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Recruiting

Phase 1

Phase 2

BDTX-1535Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Sponsor:

Black Diamond Therapeutics, Inc.

Code:

NCT05256290

Conditions

Non-Small Cell Lung Cancer

Advanced Non-Small Cell Squamous Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma

Metastatic Lung Cancer

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDTX-1535 monotherapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-20. This information was provided to ClinicalTrials.gov by Black Diamond Therapeutics, Inc. on 2025-05-31.